Intensity-Modulated Radiation Therapy Best for Locally Advanced NSCLC
FRIDAY, Sept. 15, 2023 -- Intensity-modulated radiation therapy (IMRT) shows benefits over 3D-conformal (3D-CRT) radiotherapy for patients with locally advanced non-small cell lung cancer (NSCLC), according to a study presented at the International... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 15, 2023 Category: Pharmaceuticals Source Type: news
Should NSCLC Patients Receive Immunotherapy'Indefinitely'? Should NSCLC Patients Receive Immunotherapy'Indefinitely'?
Most long-term responders to immunotherapy continue taking the drugs after 2 years. But data show long-term use likely offers no survival benefit.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 15, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
What Does Not Affect Surgical Outcomes in NSCLC? What Does Not Affect Surgical Outcomes in NSCLC?
AEGEAN is one of the first studies of immune checkpoint inhibitors in the perioperative settings to demonstrate improved EFS and pCR with no effect on surgical outcomes.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 14, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
To Resect or Not to Resect in Stage III NSCLC To Resect or Not to Resect in Stage III NSCLC
When is stage III NSCLC resectable? Experts attempted to reach a consensus on when to perform surgery.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 14, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
IMRT Best for Locally Advanced NSCLC, Study Suggests
(MedPage Today) -- SINGAPORE -- Intensity-modulated radiation therapy (IMRT) should be the radiation technique of choice for unresectable locally advanced non-small lung cancer (NSCLC), a secondary analysis of a randomized trial suggested.
In... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 13, 2023 Category: Hematology Source Type: news
Novel Antibody-Drug Conjugate Shows Efficacy in Advanced EGFR-Mutated NSCLC
(MedPage Today) -- SINGAPORE -- Treatment with the novel antibody-drug conjugate patritumab deruxtecan (HER3-DXd) after progression with an EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy resulted in "clinically meaningful... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 13, 2023 Category: Hematology Source Type: news
First-Line Osimertinib for Patients With EGFR Advanced NSCLC First-Line Osimertinib for Patients With EGFR Advanced NSCLC
What have we learned about the safety and efficacy of osimertinib for the first-line treatment of patients with EGFR-mutated advanced NSCLC?Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 13, 2023 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
ADCs Show Early Promise in NSCLC ADCs Show Early Promise in NSCLC
Antibody-drug conjugates link a tumor-targeted antibody to a cytotoxic drug through a chemical linker and hold the promise of high potency.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 13, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Osimertinib Plus Chemo Ups PFS, Toxicity in First Line Osimertinib Plus Chemo Ups PFS, Toxicity in First Line
Combining osimertinib with chemotherapy improved progression-free survival in EGFR-mutated non-small cell lung cancer, new interim data show, but experts have raised concerns about toxicity.Medscape Medical News (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - September 12, 2023 Category: Pathology Tags: Hematology-Oncology News Source Type: news
Long-term Outcomes of Radiation Techniques for Locally Advanced Non-Small Cell Lung Cancer Presented at IASLC 2023 Conference in Singapore
Intensity-modulated radiation therapy, or IMRT, should be utilized for locally advanced NSCLC to reduce the risk of severe pulmonary toxicity and radiation exposure to the heart, according to research presented today at the International Association for the Study of Lung Cancer 2023 World... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 12, 2023 Category: Pharmaceuticals Tags: SVY TRI TDS Source Type: news
Adding First-Line Chemo Boosts PFS in EGFR-Mutant Lung Cancer
(MedPage Today) -- SINGAPORE -- Treatment with osimertinib (Tagrisso) plus chemotherapy reduced the risk of disease progression or death by 38% compared with osimertinib monotherapy in patients with advanced EGFR-mutant non-small cell lung cancer... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 12, 2023 Category: Hematology Source Type: news
Surgical Outcomes of Perioperative Durvalumab in AEGEAN Study to be Presented at IASLC 2023 World Conference on Lung Cancer
Adding perioperative durvalumab to neoadjuvant chemotherapy did not adversely impact surgery in patients with resectable NSCLC and was associated with a tolerable surgical safety profile, according to research presented today from the phase 3 AEGEAN trial at the International Association... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 12, 2023 Category: Pharmaceuticals Tags: TRI TDS Source Type: news
Novel ADC Offers Hope in Heavily Pretreated NSCLC Novel ADC Offers Hope in Heavily Pretreated NSCLC
Patients with EGFR-mutated NSCLC who have progressed after multiple lines of therapy may have meaningful and durable responses to a novel antibody-drug conjugate HER3-DXd, new phase 2 data suggest.Medscape Medical News (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - September 11, 2023 Category: Pathology Tags: Hematology-Oncology News Source Type: news
Six-Year Follow-Up Data on CheckMate 227 Survival and Quality of Life Benefits Unveiled for Patients with Metastatic NSCLC and Nivolumab + Ipilimumab Treatment
SINGAPORE, Sept. 10, 2023 /PRNewswire-PRWeb/ -- The International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2023 in Singapore is set to witness a monumental breakthrough in the field of metastatic non-small cell lung cancer (NSCLC) treatment.... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 10, 2023 Category: Pharmaceuticals Tags: TRI SVY Source Type: news
Roche & #039;s Alecensa delivers unprecedented Phase III results for people with ALK-positive early-stage lung cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the Phase III ALINA study evaluating Alecensa® (alectinib), compared with platinum-based chemotherapy, met its primary endpoint of disease-free survival (DFS) at a prespecified interim analysis. Alecensa demonstrated a statistically significant and clinically meaningful improvement in DFS as adjuvant therapy in people with completely resected stage IB (tumour ≥4cm) to IIIA (UICC/AJCC 7th edition) anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). (Source: World Pharma News)
Source: World Pharma News - September 6, 2023 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news
